Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study.

"Duality of Interest. R.L.M.C. has received honoraria from Sanofi, J.M. has received speaker fees from Napp Pharmaceuticals and has been involved in CV outcome trials funded by Novo Nordisk, Eli Lilly, Boehringer, GlaxoSmithKline, and Medimmune Ltd. H.C. has received grants or institutional fees from Eli Lilly and Company, AstraZeneca LP, Pfizer, and Novo Nordisk. N.S. has consulted for Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceutical, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi, and received grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. R.J.M. has received royalties or licenses from Elsevier and honoraria from Sanofi and Novo Nordisk, and institutional fees from National Health Services Tayside and Medical Reserve Corps. E.R.P. has received honoraria from Sanofi and Eli Lilly. No other potential conflicts of interest relevant to this article were reported."

"Funding. This work was supported by Health Data Research UK which receives its funding from HDR UK Ltd (HDR-5012) funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation (BHF), and the Wellcome Trust."